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Summary 
Class II-associated invariant chain peptides (CLIPs) compete with natural allele-specific ligands 
for binding to several purified HLA-DR molecules. Truncation and substitution analysis showed 
that a minimal sequence of 13 amino acids is sufficient for excellent binding to DR17 and DR1. 
Hydrophobic residues at relative positions 1 and 9 (P1 and P9) which are shared among these 
DK-ligands, and are found to be anchored in complementary pockets by x-ray crystallography 
allow specific binding. Two flanking residues at either end next to the specific contact sites Metl0v 
and Metlts contribute to binding irrespective of their side chains,  suggesting H-bonds to the 
major histocompatibility complex (MHC) molecule. Thus, CLIPs behave like conventional ligands, 
however, lack their allele-specific contact sites.  Introduction of the DK17-specific contact site 
aspartate at P4 dramatically improves invariant chain-peptide binding to DR.17, but reduces DK1 
binding. By contrast, binding to DR1, but not DK17 is strongly improved after introduction 
of the DKl-specific contact site alanine at P6.  In addition, analyzing the fine specificity of the 
hydrophobic contact sites at P1 and P9, CLIP variants reflected the allele-specific preferences of 
DR17- or DKl-ligands, respectively, for aliphatic or aromatic residues. Alignment studies suggest 
that CLIPs are designed for promiscuous binding in the groove of many MHC class II molecules 
by taking advantage of one or more supermotifs. One such supermotif, for example, does not 
include the DK17-specific contact site aspartate at P4, which in conventional natural ligands 
like Apolipoprotein (2877-94) is necessary to confer a stable conformation. Introduction of aspartate 
at P4 generates a CLIP variant that is stable  in the presence of sodium dodecyl sulfate,  such 
as allele-specific ligands. Studying the stability of class II-CLIP complexes at pH 5, we found 
that CLIPs, similar to anchor-amputated ligands, can be released from class II molecules, in contrast 
to conventional natural ligands, which were irreversibly bound. Taken together, our data provide 
compelling evidence that CLIP peptides bind into the class II groove. 
M 
HC class II molecules are heterodimeric transmembrane 
glycoproteins that present immunogenic peptides to 
T lymphocytes. Such peptides are normally derived from the 
endocytic pathway (1, 2), whereas class I molecules predomi- 
nantly bind peptides generated from proteins synthesized in 
the cell. These functional dichotomies between class I and 
II MHC molecules are preserved by the invariant chain (Ii) 1, 
a nonpolymorphic, non-MHC-encoded transmembrane pro- 
tein (3, 4). After assembly of cr and B polypeptides with Ii 
in the endoplasmic reticulum, an NH2-terminal signal se- 
quence of Ii drives the stoichiometric complex into the en- 
1 Abbreviations used in the paper: ApoB, Apolipoprotein B; CLIP, class 
II-associated invariant chain peptide; Ii, invariant chain. 
dosomal system (5, 6). During this transport Ii prevents in- 
teraction of class II molecules with peptides or segments of 
intact proteins (3, 4). Proteolytic cleavage of the Ii in a post- 
Golgi compartment releases oe/~ dimers, making the class 
II binding site available (7). The precise mechanisms involved 
in forming class II-peptide complexes are unclear, although 
the existence of antigen processing-deficient mutants argues 
that at least one additional gene product, HLA-DM, encoded 
in the MHC region, is involved.  In such mutants, a limited 
variety of self peptides was found on MHC class II molecules 
(8-10).  The dominant sequences were derived from a dis- 
tinct region of the Ii chain and were presented as nested sets 
on either ends, with a common core (8, 9). Similar class II-as- 
sociated invariant chain peptides (CLIPs) have been found in 
wild-type cells of humans and mice (11-14),  implying that 
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cumulate in these mutants (10, 15). From several studies it 
was clear that CLIPS can compete in vitro with natural ligands 
for class II binding (8, 9, 16). However, the question remained 
how they bind to class II molecules. It is especially unclear 
whether CLIPs bind in the MHC class II binding groove, 
or at another site of the MHC molecule. Such  a question 
became more interesting, since it was recently found that the 
sequence of CLIP and the segment indispensable for Ii-class 
II interaction are related (17, 18). We reproduced the com- 
petitive effect of CLIP-binding with natural ligands and ad- 
dressed the problem of the interaction between class II and 
CLIP by studying the binding characteristics  of CLIP pep- 
tides and variants of CLIP peptides to different class II mole- 
cules. Our recent study of allele-specific contact sites of nat- 
ural DR17 ligands (19, 20) prompted us to choose HLA-DE17 
and HLA-DR1 alleles that have been found to be associated 
with CLIPs in vivo. The latter were intensively studied for 
their binding motifs (21-24) and crystallographic data provided 
evidence how contact sites of natural ligands are accommo- 
dated in the DR.1 peptide binding groove (25, 26). Compara- 
tive studies of CLIP-binding motifs with motifs of conven- 
tional natural class II ligands and modulation at allele-specific 
contact sites revealed a high degree of compatibility, suggesting 
CLIP-binding in the peptide binding groove. 
Materials and Methods 
CelILines and Antibodies.  EBV-transformed  human B cells from 
a local homozygous donor (RUP, DR17, and DR52a, confirmed 
by oligonucleotide typing) and LG2 cells (DR1) were grown in 
RPMI 1640 medium (Gibco, Eggenstein, Germany) supplemented 
with 10%  FCS (Boehringer-Mannheim, Mannheim, Germany), 
20 mM Hepes, 2 mM glutamine, and antibiotics and expanded in 
roller bottles  to 0.5  x  101~  x  101~  cells. 
mAb L243 obtained from the American Type Culture Collec- 
tion (Rockville, MD) was used for immunoprecipitation of MHC 
molecules and analysis  of native HLA-DR17 or HLA-DR1 mole- 
cules in ELISA. mAb L243 binds to a nonpolymorphic  determinant 
present on DR molecules. 
HLA-DR  Purification.  The purification of HLA-DR17  and 
HLA-DR1 molecules from homozygous EBV-transformed  B cell 
line ILUP or LG2 using L243-coupled, CNBr-activated Sepharose 
(Pharmacia, Freiburg, Germany) was performed as described (20). 
DR1 or a mixture of HLA-DR17/52a molecules was eluted with 
25 mM Na2CO3, 0.15 M NaC1, 0.1% NP40, and 0.1 mM PMSF, 
pH 11.0, neutralized immediately with 50 mM Tris/HC1 at pH 
8.4 an stored at 4~  until use. 
Peptides.  Peptides  were synthesized on a multiple synthesizer 
(model SMPS 350; Zinsser  Analytik, Frankfurt/M, Germany)  using 
Fmoc/tBu strategy and purified by reversed phase HPLC (model 
600; Waters, Eschborn, Germany) to achieve a purity of >90%. 
Structure and purity were confirmed by electrospray mass spec- 
trometry (model API III; Sciex, Toronto, Canada). Apolipoprotein 
(Apo) B(2877-2894) and HLA-A2(103-117) were NH2-terminally 
biotinylated on line by five coupling steps forming Biotin-e-Lys- 
~-Ala-Ahx-~-Ala-[ApoB100 2877-2894] or in solution by a 3.5 
molar excess  of  biotinyl-e-aminocaproyl-N-hydroxysucdnimide  ester 
BACNHS; Sigma Chemical Co., St. Louis, MO) at 200C for 2 h. 
Peptide Binding Assay.  The peptide binding assay  was performed 
as described  by Jensen (27) and elsewhere  (20). Briefly,  purified  HLA- 
DR molecules (100 nM) were incubated at 37~  with 2/~M bio- 
tinylated agonist with or without competitor peptide in 96-well 
microtiter plates (Greiner, N~irtingen, Germany) in binding buffer 
(50/~1) containing 25 mM Na-carbonate, 50 mM Tris, 2 mM EDTA, 
0.01% azide, 0.1 mM PMSF, and 0.1% NP40 adjusted to pH 5 
by 1 M citrate. After 72 h, MHC-peptide complexes were sepa- 
rated from free peptides  by immunoprecipitation  with immobilized 
L243 and detected by successive incubation at 20~  with strep- 
tavidin (10/~g/ml) and biotinylated peroxidase (1 ng/ml; both from 
Dianova, Hamburg, Germany) for 45 min, respectively,  followed 
by incubation with ABTS (1 mg/ml; Boehringer-Mannheim).  The 
absorbance at 405 nM was measured by an ELISA reader (Mul- 
tiskan Plus; Titertek, Meckenheim, Germany) after about 45 min, 
and nonspecific  signals (quadruplicates, typically 15% of maximal 
absorbance) were subtracted from the data. 
Stability of Class II-Ligand Complexes.  100 nM DE17 mole- 
cules was preloaded  with 2/xM biotinylated  peptides for 4 d (37~ 
pH 5) and separated from excess peptides by 10-K ultrafiltration 
(Amicon Corp., Beverly, MA). The time course of dissociation of 
DR17 complexes in the presence of 100/zM unlabeled  ApoB(2877- 
2892) was determined by incubation at 37~  pH 5 and stable  com- 
plexes were detected as described in the previous paragraph. 
SDS-PAGE and Western Blot Analysis.  HLA-DR17  molecules 
were isolated from the homozygous EBV-transformed B cell line 
RUP or LG2 as described above (20). 1/zM class II molecules was 
incubated for 3 d in binding buffer at pH 5 in the presence of 25 
/xM peptide and neutralized by addition of 50 mM Tris, pH 8.8. 
An equal volume of 2 ￿  nonreducing Laemmli sample buffer was 
added and samples were run on 10% SDS-PAGE. After transfer 
(Multiphor; Pharmacia) the Nylon membrane was blocked with 
6% Casein/0.05% Na-azide/10 mM EDTA/PBS, pH 7.4, subse- 
quently treated with streptavidin (2.5/zg/ml), and complexes were 
detected with biotinylated alkaline phosphatase (100 ng/ml) and 
chemiluminiscence. 
Results and Discussion 
Overlapping peptides corresponding to the Ii sequence Ii 
(97-120) (numbering from the NH2 terminus of the longer 
p35 form) (28) were synthesized. Peptides were initially tested 
for their ability to compete with the natural DR17 ligand 
Apolipoprotein  B100  [ApoB(2877-2894)]  for  binding  to 
purified HLA-DR17 (20). MHC-peptide association was per- 
formed in solution at pH 5, shown to be optimal for natural 
ligands including CLIP(97-120)  to bind to DR17 (data not 
shown). Fig.  I a shows the inhibiting effect of six Ii 12-mer 
peptides versus 2 #M ApoB(2877-2894).  Ii(106-117) com- 
peted in a dose-dependent manner, whereas the other pep- 
tides showed no effect.  Thus, only Ii(106-117),  a sequence 
contained in all Ii ligands found on DR molecules,  blocked 
the binding of ApoB(2877-94)  to DR17. 
To study the binding of Ii(106-117) in detail, we analyzed 
contact residues  of the 12-met by single Ala substitutions. 
At most positions we observed only slight shifts in the binding 
capacity (Fig.  1 b). However, Ala substitutes for Mett07 or 
Met115 did not or did only marginally compete,  even at high 
concentrations, corresponding to a decrease of the binding 
capacity of at least  100- and 10-20-fold, respectively  (Fig. 
1 c). This notion is consistent with the failure of Ii(97-113) 
(data  not  shown),  Ii(103-114),  and Ii(109-120)  (Fig.  1 a), 
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Figure  1.  Ability of increasing amounts of Ii 12-mers derived from the CLIP sequence and variants of Ii(106-117) to compete with 2/zM biotinylated 
ApoB(2877-2894)  for binding to purified DR17 molecules. Binding of biotinylated Apo(2877-2894) in the absence of competitor was 0.599  +  0.021 
(a),  0.602  ++.  0.032 (b and d), and 0.507  ++_ 0.017 (c) OD40s  U  (quadruplicates). Nonspecific  signal in the absence of MHC molecules was 0.063  _+ 
0.003 (a), 0.084  _+ 0.002 (b and d), and 0.065 (c) (quadruplicates). Percent inhibition of agonist-binding,  performed in duplicates, was expressed using 
the formula: 1  -  [(signal with competitor  -  background/signal  without competitor  -  background)]  x  100%. 
lacking either Meh07 or Metn5, to compete with ApoB(2877- 
2894) for binding to DR17. Moreover both methionines are 
contained in the nested set of CLIPs.  In conclusion, we have 
identified  two  hydrophobic  DR17  contact  sites  of CLIPs, 
Meq07 and Mehts. 
Phe or Leu substitution for Metns resulted in a lesser de- 
crease of the binding capacity as compared with the Ala sub- 
stitution,  whereas  the same  substitutions  of Meh07  main- 
tained  the parental binding capacity of Ii(106-117)  or even 
improved it (Fig. 1 d). Thus, a conservative exchange for hy- 
drophobic residues like leucine or phenylalanine can replace 
Met107 and Metns better than the small alanine.  Aspartate 
at these positions completely disrupt binding (data not shown). 
We could reconfirm these findings with CLIP(97-120)  and 
therefore rule out a different mechanism  in binding of the 
longer CLIPs compared with the truncated forms (data not 
shown). 
Meh07 and Metns are spaced by seven  amino acids. This 
is the same spacing of hydrophobic/aromatic  contact residues, 
at relative position P1 and P9, as found in natural D1L17 ligands 
interacting with the peptide binding groove (19, 20, and Table 
1). In addition to this partial homology between Ii(106-117) 
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 Figure  2.  Binding  of Ii-peptides, variants, and specific  DR17 ligands to DR17 molecules. In competition assays the binding capacity  of  CLiP(97-120) 
was compared  with truncated variants (a) and to the specific  DR17 ligands (9) (Low density lipid receptor [LDLR], IFN-'y receptor [ylF-R], transferrin 
receptor [TF-R]) TF-R (140-56), a natural DR1 ligand was included as a control (b). The contribution of flanking residues on binding was investigated 
by removal (a) or substitution of single amino acids next to the hydrophobic contact sites Met107 or Metlls (c). Binding of biotinylated ApoB(2877- 
2894) in the absence of competitor was 0.602 _+ 0.034 (a and c) and 0.735  +  0.034 (b) OD40s U (quadruplicates). Nonspecific  signal in the absence 
of MHC-molecules was 0.084 -+ 0.002 (a and c) and 0.057 -+ 0.002 (b) (quadruplicates). SDS stabilization of HLA-DR17 dimers under nonreducing 
conditions analyzed in Western blot in the presence of natural DR17 ligands and their variants, altered at the allele-specific contact site (d). In the 
presence of DTT no signal was detectable (not shown). 
CLIPs of natural length is likely due to the flanking residues. 
Removal of the 8  NH2-terminal  and of the 3  COOH-ter- 
minal residues [Ii(105-117)] had little effect on binding (Fig. 
2 a). However, further removal reduced the binding capacity 
dramatically (Fig.  2 a).  To determine  the specificity of the 
four residues Serl05, K106, Ql16, and A117, which were obvi- 
ously contact sites outside the core region, these amino acid 
residues were substituted for a variety of amino acids. It did 
531  Malcherek  et al. not matter whether such flanking residues were substituted 
for Ala (Fig. 2 c) or even for charged residues (data not shown), 
since the parental binding capacity of Ii(106-117) was always 
retained. These data indicate that residues at positions 105, 
106 and 116, 117 are necessary for binding, but irrespective 
of their side chains. A similar contribution on binding was 
previously shown for cytochrome c peptides and demonstrated 
for the flanking regions of I-A  k- and DR17-specific ligands 
(20, 29,  30) and it is likely that such flanking residues are 
forming H-bonds to the MHC molecule as illustrated for 
HA(307-319) bound to DR1 (26). Thus, our results support 
the view that CLIPs bind in the DR17-peptide binding groove, 
like allele-specific  ligands. 
X-ray crystallography has dearly demonstrated how a ligand 
is accommodated by pockets along the peptide binding groove 
of the DR1 molecule, thereby explaining postulated ligand 
and binding motifs (14,  21-26).  We therefore extended on 
CLIP-binding studies to DR1. Purified DR1 molecules were 
loaded with biotinylated natural DR1 ligand HLA-A2(103- 
117) and competition by Ii-peptides was measured. Among 
the six 12-mers tested, Ii(106-117), the peptide which contained 
contact sites for DR.17 binding, was the best inhibitor (Fig. 
3 a). This finding is not unexpected, since this sequence is 
contained in each CLIP found on DR1. Studying the con- 
tact sites within the 12-mer Ii(106-117) we again found that 
Met107 and Met115 efficiently contribute to binding (Fig.  3 
b). Such results were reproduced with the long CLIP(97-120) 
and confirmed that  the dominant contact sites  are Met107 
and Metlls (data not shown). The effects upon Ala substi- 
tution of these methionines on DR1 binding are significant 
although less impressive than those observed on DR17 binding, 
but became striking upon substitution for any charged res- 
idue (Figs.  1 c and 3 b, data not shown). Furthermore, sub- 
stitution of Ml07 for phenylalanine strongly improved the ca- 
pacity of Ii(106-117)  to bind to DR1  (Fig.  3 c) but not to 
DR17  (Fig.  1 d).  Such results are consistent with the fine 
specificity of DP,1 and DR17 ligands at P1. Aromatic residues 
dominate over aliphatic residues at P1 among DR1 ligands 
(21-24), whereas the opposite preferences were found for DR17 
ligands (19, 20). In the same vein, the effects on binding upon 
substitution  of Met115 can be interpreted. Substitution  for 
alanine  showed a  less  impressive reduction  than  that  for 
phenylalanine, whereas substitution for leucine even improved 
binding to DIK1 (Fig. 3 c). These results are in perfect agree- 
ment with the fine specificity of D1K1 ligands at P9 (24). 
Leucine dominates over methionine and an equivalent fre- 
quency was observed for alanine,  whereas phenylalanine is 
not preferred. Thus, we have shown that CLIPs share M107 
and Mus as contact sites P1 and P9 for DR1 and DR17 mol- 
ecules.  The side chain at P4 can be accommodated by the 
second pocket of the DR1 binding groove (26).  P4 of DR1 
ligands is predominantly occupied by residues with aliphatic 
side chains (14, 24). Leucine occupies P4 of the natural DIK1 
ligand HLA-A2(103-117) and alanine occupies P4 of CLIPs. 
The importance of aliphatic residues in these ligands was 
demonstrated upon Asp substitutions. In any case, the binding 
capacity dramatically dropped (Fig.  3,  b and d).  Thus,  the 
same substitution shows strikingly different effects on CLIP- 
binding to D1K1 and DIK17, which is consistent with the 
allele-specific binding requirements of class II ligands at P4, 
aliphatic  residues  in  DR1,  aspartate  in  DR17  ligands. 
Moreover, introduction of the DRl-specific contact site ala- 
nine at P6 (14, 24) improved the binding capacity of the Ii- 
peptide dramatically (Fig. 3 c). In summary, we have shown 
how CLIPs adapt to different allele-specific requirements. Side 
chain-dependent as well as -independent (data not shown 
for DR1)  contact sites  of CLIPs fit perfectly with natural 
allele-specific ligands of DR1 and DR17. The use of hydro- 
phobic contact sites common among DR ligands (Table 1) 
enable CLIPs to bind well to different class II molecules in- 
cluding DR17, which has an unusual and highly specific ligand 
motif (19). The lack of allele-specific contact sites in CLIPs 
is useful to keep potential negative effects at a minimum, 
particularly avoiding charged residues (20, 31) which could 
jeopardize binding to other class II molecules. Thus, CLIPs 
appear to be designed to be promiscuous MHC binders. This 
is illustrated in the excellent binding capacity of CLIPs found 
to be associated  with DR17 and DR1  (9,  16 and Figs.  2 b 
and 3 e). 
In addition to DR17 and DR1, CLIPs were found to be 
associated with a variety of class II molecules (11-14). Align- 
ment studies suggest that CLIPs possess a sequence compat- 
ible with motifs of different class II alleles and isotypes (Table 
1). CLIPs, for example, found to be associated with DR4Dw4 
on T2 transfectants (32) use the same minimal sequence as 
D1K1 and DR17  for binding with Met107 as main anchor 
(Malcherek, G., and A. Melms, unpublished results).  Metns 
does not serve as anchor at Pg, the position,  which is not 
conserved by hydrophobic residues within DR4Dw4 ligands 
(24).  These allele-specific  effects should have consequences 
on the capacity to bind to DR4Dw4.  Indeed, the capacity 
of CLIP(97-120) to compete with natural D1K4Dw4 ligands 
is reduced in vitro (Malcherek, G., and A. Melms, unpub- 
lished results) and probably in vivo,  explaining the absence 
of CLIPs on DR4Dw4 wild-type cells. In consequence, CLIPs 
have the ability to bind to a series of HLA-DIK allele prod- 
ucts by taking advantage of supermotifs, which enable vari- 
able binding affinities depending on the respective allele (32). 
These supermotifs are not limited to the arrangement of con- 
tact sites of HLA-DR ligands, but are also compatible with 
motifs of isotypes like HLA-DQ (Table 1). Common to all 
these motifs is the use of a core sequence, which completely 
lacks  a third of the NH2-terminal part of the long CLIP- 
form Ii(97-120)  for binding (Table  1). 
From our data it becomes clear that CLIPs cannot fully 
meet the optimal allele-specific requirements of all class II 
motifs. CLIPs appear to have found a balance by avoiding 
residues resulting in high affinity for some alleles but adverse 
effects for others. 
Figs.  1 and 3 show, that the lack of allele-specific contact 
sites does not preclude the excellent binding capacity of CLIPs. 
However, this lack becomes apparent if the MHC dimer sta- 
bility in the presence of SDS is studied. CLIP(97-120) is not 
able to generate SDS-stable complexes with DR17 (8,  and 
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533  Malcherek et al. Fig.  2 d),  whereas ApoB(2877-2894)  does (Fig.  2 d).  SDS 
stability of the latter is lost if we substitute Asp2ss4 for Ala 
at P4 (Fig.  2 d). Nevertheless, the variant retains a high ca- 
pacity for binding to DR17 (data not shown). Thus, excel- 
lent binding in the MHC peptide binding groove does not 
necessarily coincide with SDS-stable association (30).  Fur- 
thermore, the stability of HLA-DR17 ct/13 dimers appears 
to be dependent on the presence of the DR17-specific con- 
tact site aspartate. Aspartate introduced in CLIP(97-120) at 
P4 confers to SDS resistance (Fig.  2 d).  In the same vein, 
complexes of HLA-DR4, DR11 with CLIPs are unstable in 
the presence of SDS (32), in contrast to complexes of DR1 
with CLIPs (data not shown; 16). CLIPS are able to provide 
more specific contact sites for interaction with DR1 than with 
DR17, DR4, or DR11 (24, and Table 1). Thus, our findings 
clearly show that the different behavior in SDS is a direct 
consequence of CLIP binding after allele-specific rules and 
argues in favor rather than against groove binding (17). 
High affinity, antigenic peptides are irreversibly associated 
with class II molecules in living cells (33),  inducing a con- 
formation required for surface expression. Once formed, this 
association is irreversible in the presence of SDS (34, and Fig. 
2 d) and even in the presence of high amounts of conven- 
tional natural ligands (Fig.  3 e). In contrast, CLIPs behave 
like anchor-amputated variants of allele-specific ligands. These 
do not usually induce SDS stability and can be released from 
the binding groove by competing natural ligands at low pH 
(35,  and Fig.  3 e).  The intact Ii, however, blocks peptide 
binding  until  reaching  the class  II  loading  compartment 
(36-39).  The physiological effects on antigen presentation 
are evident in Ii-negative cells, which express a different array 
of antigenic peptides. Some new peptides not seen on normal, 
Ii-positive cells occur, whereas other peptides are missing (40). 
Thus, Ii apparently determines presentation of antigenic pep- 
tides, probably also in the form of CLIPs succeeding the Ii. 
Our data indicate that CLIPs are fitted to bind into class II 
grooves, and that they can be replaced by high affinity, allele- 
specific ligands. Thus the role of CLIPs as anchor-amputated 
substitutes of allele-specific ligands could be, because of their 
nature as peptides,  to provide a mechanism for effectively 
loading of class II molecules with antigenic peptides.  Thereby 
CLIPs might also select binding of antigenic peptides in a 
way that binding of low affinity peptides present in the class 
II loading compartment is avoided, and the access to the groove 
is limited for high affinity ligands only. 
Under  this  hypothesis,  removal of displaced CLIPs  by 
HLA-DM molecules, possibly serving as a sink for CLIPs, 
appears to be a prerequisite for efficient loading of allele-specific 
ligands, since the class II molecules of HLA-DM-defective 
cells are predominantly occupied by CLIPs (10, 41). In sum- 
mary, our data provide compelling evidence that CLIPs as 
free peptides bind in the class II binding groove. This is the 
direct conclusion from studies focused on CLIPs performed 
at the peptide level. Our studies do not exclude, however, 
a second mode of CLIP-binding to class II molecules at a 
site other than the groove, as has been postulated by Krop- 
shofer et al.  (42).  In our present studies we have addressed 
the question of how CLIPs bind to class II molecules, but 
we cannot determine when this interaction occurs. Recent 
findings that CLIPs are almost identical to a region of Ii in- 
dispensable  for binding to class II molecules (17, 18) argued 
for a single binding site of CLIP as a free peptide and CLIP 
as a part of the Ii. The possibility that the intact Ii already 
occupies and prevents access to the binding groove cannot 
be ruled out. Polypeptides, in general, have the ability to bind 
to class II molecules and are able to compete with natural 
ligands (43, and Malcherek, G., and A. Melms, unpublished 
observations). Ii as a whole molecule exhibits an extending 
conformation (44),  which should facilitate groove binding 
via the CLIP segment. Moreover, the instability in the pres- 
ence of SDS coincides between class II-Ii and class II-CLIP 
complexes (4, 8, 32, 34, and Fig.  2 at), a feature shown not 
to be in contradiction with groove binding. An alternative 
explanation for the generation of class II-CLIP complexes 
is that CLIPs happen to be class II binding peptides which 
are released upon Ii proteolysis and subsequently compete with 
endocytically  generated  peptides  for  groove  binding.  A 
mutagenesis-based study  focused on  specific  residues  and 
shown in our study to be important for binding should help 
to determine whether the CLIP region interacts with the 
class II binding groove in the intact ol/3-Ii complex as well. 
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